InvestSMART

Starpharma Holdings Limited (ASX:SPL)

ALERT: Price-sensitive ASX Announcement for SPL
Current share price for SPL : $0.725 0.505 (229.55%)+
Announcement
Release
30 Sep 2025 9:45AM
Price at Release
$0.220
Full Release
download
Summary
Starpharma Holdings Limited has entered into a research and option agreement with Radiopharm Theranostics to develop a dendrimer-drug conjugate that incorporates a radiopharmaceutical molecule using Starpharma's DEP® platform technology. This partnership, which follows six months of preliminary research, marks Starpharma's first foray into radiopharmaceuticals and is an extension of its Star Navigator program. The agreement entails Starpharma receiving R&D service and manufacturing fees immediately, along with an option for Radiopharm to license the asset, which includes a potential AUD $0.5 million option fee. Upon successful licensing, Starpharma could receive up to AUD $89 million in milestones and royalties. This collaboration signifies a strategic step for Starpharma in leveraging its dendrimer technology in the fast-evolving field of radiopharmaceutical drug development while maintaining its internal focus on targeted cancer therapies.
Key Points
  • Starpharma has signed a research and option agreement with Radiopharm Theranostics.
  • The partnership involves developing a dendrimer-drug conjugate using Starpharma's DEP® technology.
  • Starpharma will receive R&D service and manufacturing fees initially.
  • Radiopharm has an exclusive option to license the developed asset.
  • The agreement includes the potential for Starpharma to earn up to AUD $89 million in milestones.
  • This is Starpharma's first radiopharmaceutical partnership and first project from the Star Navigator program.
  • The collaboration underscores the strategic value of Starpharma's dendrimer technology in oncology.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.